Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Key facts

Study ID

NCT00116896

Run by

OSI Pharmaceuticals

People needed

25

Starts

2003-06-01

Expected to finish

2004-12-01

Last updated by the study team

2009-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Advanced and/or metastatic solid tumor for which no effective therapy is available
• ECOG performance status 0-2
• Adequate bone marrow, hepatic and renal function

You may not qualify if…

• Patients with active or uncontrolled infections
• Neurotoxicity >= Grade 2
• Symptomatic brain metastases which are not stable

Where it is running

• Vanderbilt Universtiy Medical Center — Nashville, Tennessee, United States
• Institute for Drug DevelopmentCancer Therapy & Research Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.